1. Home
  2. IMNM vs CXT Comparison

IMNM vs CXT Comparison

Compare IMNM & CXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.12

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Crane NXT Co.

CXT

Crane NXT Co.

HOLD

Current Price

$51.65

Market Cap

2.9B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
CXT
Founded
2006
1855
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Office Equipment/Supplies/Services
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.9B
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
IMNM
CXT
Price
$22.12
$51.65
Analyst Decision
Strong Buy
Buy
Analyst Count
10
4
Target Price
$32.80
$73.00
AVG Volume (30 Days)
1.7M
1.1M
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
1.65%
EPS Growth
51.40
N/A
EPS
N/A
0.11
Revenue
$6,941,000.00
$3,374,900,000.00
Revenue This Year
N/A
$5.75
Revenue Next Year
$1,127.34
$4.22
P/E Ratio
N/A
$469.91
Revenue Growth
N/A
6.13
52 Week Low
$8.67
$35.71
52 Week High
$27.65
$69.00

Technical Indicators

Market Signals
Indicator
IMNM
CXT
Relative Strength Index (RSI) 52.69 65.57
Support Level $19.28 $50.05
Resistance Level $23.25 $53.57
Average True Range (ATR) 1.36 1.86
MACD -0.03 -0.10
Stochastic Oscillator 45.98 64.52

Price Performance

Historical Comparison
IMNM
CXT

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About CXT Crane NXT Co.

Crane NXT Co is a industrial technology company that provides proprietary and trusted technology solutions to secure, detect, and authenticate what matters to its customers. It is a pioneer in proprietary micro-optics technology for securing physical products, and its sophisticated electronic equipment and associated software leverages proprietary core capabilities with detection and sensing technologies. The company operates in two segments which are Crane Payment Innovations (CPI) and Security and Authentication Technologies.

Share on Social Networks: